QUIXIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIXIN is an ophthalmic solution approved in 2000 for eye infections, delivered as topical drops. The exact mechanism of action and indications are not publicly detailed in available data, but the small-molecule formulation targets localized ocular pathology.
LOE Approaching
Product approaching loss of exclusivity with 76 linked roles concentrated in Finance and Commercial, suggesting active cost-management and transition planning across regional markets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUIXIN roles are concentrated in Finance and Commercial functions across Asia-Pacific, reflecting Santen's regional market focus and LOE transition strategy. Career paths emphasize cost optimization, market access, and generic competition management rather than clinical innovation.
[Singapore] Head of FP&A[Singapore] Global Safety Vigilance Risk Management Lead
Worked on QUIXIN at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.